Developer docs
API playgroundTry for free, no card

Search company profiles

Psyomics

Full company profile

uuid0002fcd

Namestring
Psyomics
Legal namestring
Psyomics Ltd
Websiteurl
psyomics.com
Company typeenum
Private
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
mental health assessments, digital health platform, neurodiversity screening, clinical decision support, behavioral health software
Industry2 codes
PRIMARYHLALAEAJ
Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching)
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Prepackaged Software7372
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Mental Health Assessment Software
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1SaaS Platform Subscription
TypeSubscription Recurring
Description

B2B SaaS platform providing mental health and neurodiversity assessment tools to healthcare providers including NHS Trusts, with subscription-based licensing model. The platform is sold through enterprise sales motion with discovery, proposal, implementation, and ongoing support phases.

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1beseen
Description

Digital platform for neurodiversity covering ADHD, autism, and dual assessments for adults and young people. Developed in collaboration with NHS trusts to help manage neurodevelopmental referral backlogs.

einpresswire.com
+2 more records
Core offering1 text field

Psyomics sells AI-driven digital health assessment software (beseen and Censeo platforms) to healthcare providers for behavioral health and neurodiversity screening in adult, children and young people, and ADHD/autism pathways. The offering is delivered as a B2B SaaS subscription with EPR/EHR integration, implementation, and go-live support, and is augmented by an in-development dry blood spot Bipolar Biomarker test that combines metabolomic data with online questionnaires via machine learning.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 78% patient assessment completion rate
+5 more records
Product overview1 text field

Psyomics offers a suite of digital health products centered on the beseen platform, which provides integrated digital automation for behavioral health assessments. The platform includes specialized modules for Adult services (beseen Adult) and Young People services (beseen Young People), as well as a neurodiversity module (beseen for neurodiversity) covering ADHD and autism assessments. The company also offers the Censeo AI-driven mental health platform in partnership with clinical providers, and is developing a Bipolar Biomarker test that uses biological markers combined with digital analysis to differentiate between depressive disorders.

Product and service6 records
1beseen
CategoryDigital health platform
Description

AI-driven digital health platform for behavioral health and neurodiversity assessments that streamlines clinical workflows and reduces administrative burden across adult and young people populations.

2beseen Adult
CategoryDigital health platform module
Description

Integrated digital automation solution for adult behavioral health assessments, delivering structured data and free text reports wherever needed in the care pathway.

3beseen Young People
CategoryDigital health platform module
Description

Assessment platform for children and young people combining inputs from children, families, and professionals into one structured report for integrated care from the first contact.

4beseen for neurodiversity
CategoryDigital health platform module
Description

Digital platform for ADHD, autism, and dual assessments for adults and young people, designed to manage neurodevelopmental referral backlogs across NHS Trusts, Integrated Care Boards, and regional networks.

5Censeo
CategoryDigital health platform
Description

AI-driven mental health platform deployed at UK clinical locations in partnership with the Priory Group, focusing on reducing waiting times and improving assessment quality.

6Bipolar Biomarker
CategoryDiagnostic test
Description

Dry blood spot test combined with machine learning algorithms to differentiate between Major Depressive Disorder and Bipolar disorder, aiming to reduce misdiagnosis.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Midlands Partnership University NHS Foundation Trust
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-23
Description

Collaborative development of beseen platform for neurodiversity covering ADHD, autism, and dual assessments. The platform helps NHS services manage rising neurodevelopmental referral backlogs, with early modelling showing potential 30% reduction in clinical time.

htworld.co.uk
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-13
Description

Partnership to enhance mental health care access across several London boroughs serving over 1.6 million residents, as part of a broader transformation programme to improve care and streamline referrals.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Priory Group partnered with Psyomics to deploy its AI-driven Censeo platform at UK clinical locations, enabling improved mental health assessment capabilities across Priory's clinical network.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based AI-driven mental health platform offering NHS-facing digital triage, self-referral and assessment tools. Highly comparable to Psyomics' Censeo/beseen offering in terms of NHS GTM, AI-based patient intake, and focus on reducing waiting lists.

TypeDirect peer
Description

Provides QbTest, an FDA-cleared objective ADHD assessment combining continuous performance test data with clinical information. Directly comparable to Psyomics' beseen for neurodiversity ADHD assessment offering in clinical positioning and NHS deployment.

TypeDirect peer
Description

Digital therapeutics company with FDA-cleared products (EndeavorRx) for ADHD and cognitive conditions. Comparable to Psyomics in combining software-based cognitive/behavioral assessment and intervention for neurodiversity populations.

TypeDirect peer
Description

Digital biomarker company using AI/ML on smartphone-based cognitive assessments for early detection of neurological conditions. Directly comparable to Psyomics in the digital biomarker / SaMD evidence-generation pathway for neuropsychiatric conditions.

TypeDirect peer
Description

UK-based digital cognitive assessment company selling into clinical trials, NHS and pharma. Highly comparable in Cambridge roots, NHS-aligned cognitive/behavioral assessment products, and focus on digital endpoints for CNS conditions.

TypeDirect peer
Description

UK CNS-focused company developing biomarkers, digital health tools and clinical trial services for depression, anxiety and cognition. Closely comparable to Psyomics' bipolar biomarker and CNS diagnostic strategy, particularly the metabolomic/biological diagnostic angle.

TypeBroad incumbent
Description

Digital mental health platform offering CBT-based therapeutic programs, now part of Amwell. Comparable as an established NHS-deployed digital mental health SaaS provider, though its focus is on therapeutic content rather than assessment and triage.

TypeDirect peer
Description

Digital cognitive assessment platform using AI on speech and tablet-based tests to detect early cognitive impairment. Comparable to Psyomics in the digital biomarker / AI assessment space and in targeting primary care and clinical decision support.

TypeRegional player
Description

Large UK digital home healthcare provider using technology-enabled care services. Comparable as a UK digital health platform selling into NHS Trusts and integrated care systems with measurable efficiency outcomes.

TypeRegional player
Description

UK-based digital health platform providing virtual consultations and mental health services. Comparable as a UK private/regulated digital health operator with NHS-facing relationships and enterprise distribution motion.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Psyomics

Mental Health Assessment Softwarepsyomics.com

Psyomics firmographics

Firmographics
Name
Psyomics
Legal name
Psyomics Ltd
Website
https://psyomics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Psyomics industry classification

Industry
Product category
Mental Health Assessment Software
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Services-Prepackaged Software (7372), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLALAEAJ
Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching)
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Mental health assessments
  • Digital health platform
  • Neurodiversity screening
  • Clinical decision support
  • Behavioral health software

Where Psyomics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Markets served

Psyomics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. SaaS Platform Subscription: B2B SaaS platform providing mental health and neurodiversity assessment tools to healthcare providers including NHS Trusts, with subscription-based licensing model. The platform is sold through enterprise sales motion with discovery, proposal, implementation, and ongoing support phases.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Psyomics product offering

Product offering

Core offering

Psyomics sells AI-driven digital health assessment software (beseen and Censeo platforms) to healthcare providers for behavioral health and neurodiversity screening in adult, children and young people, and ADHD/autism pathways. The offering is delivered as a B2B SaaS subscription with EPR/EHR integration, implementation, and go-live support, and is augmented by an in-development dry blood spot Bipolar Biomarker test that combines metabolomic data with online questionnaires via machine learning.

Product overview

Psyomics offers a suite of digital health products centered on the beseen platform, which provides integrated digital automation for behavioral health assessments. The platform includes specialized modules for Adult services (beseen Adult) and Young People services (beseen Young People), as well as a neurodiversity module (beseen for neurodiversity) covering ADHD and autism assessments. The company also offers the Censeo AI-driven mental health platform in partnership with clinical providers, and is developing a Bipolar Biomarker test that uses biological markers combined with digital analysis to differentiate between depressive disorders.

Differentiator

Problem solved

Functional benefit

Brands

  • beseen: Digital platform for neurodiversity covering ADHD, autism, and dual assessments for adults and young people. Developed in collaboration with NHS trusts to help manage neurodevelopmental referral backlogs.
  • beseen young people
  • Bipolar Biomarker

Products and services

  • beseen AI-driven digital health platform for behavioral health and neurodiversity assessments that streamlines clinical workflows and reduces administrative burden across adult and young people populations.
  • beseen Adult Integrated digital automation solution for adult behavioral health assessments, delivering structured data and free text reports wherever needed in the care pathway.
  • beseen Young People Assessment platform for children and young people combining inputs from children, families, and professionals into one structured report for integrated care from the first contact.
  • beseen for neurodiversity Digital platform for ADHD, autism, and dual assessments for adults and young people, designed to manage neurodevelopmental referral backlogs across NHS Trusts, Integrated Care Boards, and regional networks.
  • Censeo AI-driven mental health platform deployed at UK clinical locations in partnership with the Priory Group, focusing on reducing waiting times and improving assessment quality.
  • Bipolar Biomarker Dry blood spot test combined with machine learning algorithms to differentiate between Major Depressive Disorder and Bipolar disorder, aiming to reduce misdiagnosis.

Quantifiable outcome

  • 78% patient assessment completion rate
  • +5 more outcomes

Companies that use Psyomics

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Psyomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Psyomics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Midlands Partnership University NHS Foundation TrustcoreStrategic or Co-development Partner · 23 January 2026Collaborative development of beseen platform for neurodiversity covering ADHD, autism, and dual assessments. The platform helps NHS services manage rising neurodevelopmental referral backlogs, with early modelling showing potential 30% reduction in clinical time.
  • North London NHS Foundation TrustcoreStrategic or Co-development Partner · 13 October 2025Partnership to enhance mental health care access across several London boroughs serving over 1.6 million residents, as part of a broader transformation programme to improve care and streamline referrals.
  • Priory GroupcoreImplementation/ SI/ Consulting PartnerPriory Group partnered with Psyomics to deploy its AI-driven Censeo platform at UK clinical locations, enabling improved mental health assessment capabilities across Priory's clinical network.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Psyomics competitors and assessment

Company assessment

Direct peers

  • Limbic: UK-based AI-driven mental health platform offering NHS-facing digital triage, self-referral and assessment tools. Highly comparable to Psyomics' Censeo/beseen offering in terms of NHS GTM, AI-based patient intake, and focus on reducing waiting lists.
  • Qbtech: Provides QbTest, an FDA-cleared objective ADHD assessment combining continuous performance test data with clinical information. Directly comparable to Psyomics' beseen for neurodiversity ADHD assessment offering in clinical positioning and NHS deployment.
  • Akili Interactive: Digital therapeutics company with FDA-cleared products (EndeavorRx) for ADHD and cognitive conditions. Comparable to Psyomics in combining software-based cognitive/behavioral assessment and intervention for neurodiversity populations.
  • Altoida: Digital biomarker company using AI/ML on smartphone-based cognitive assessments for early detection of neurological conditions. Directly comparable to Psyomics in the digital biomarker / SaMD evidence-generation pathway for neuropsychiatric conditions.
  • Cambridge Cognition: UK-based digital cognitive assessment company selling into clinical trials, NHS and pharma. Highly comparable in Cambridge roots, NHS-aligned cognitive/behavioral assessment products, and focus on digital endpoints for CNS conditions.
  • P1vital: UK CNS-focused company developing biomarkers, digital health tools and clinical trial services for depression, anxiety and cognition. Closely comparable to Psyomics' bipolar biomarker and CNS diagnostic strategy, particularly the metabolomic/biological diagnostic angle.
  • Linus Health: Digital cognitive assessment platform using AI on speech and tablet-based tests to detect early cognitive impairment. Comparable to Psyomics in the digital biomarker / AI assessment space and in targeting primary care and clinical decision support.

Broad incumbents

  • SilverCloud Health (Amwell): Digital mental health platform offering CBT-based therapeutic programs, now part of Amwell. Comparable as an established NHS-deployed digital mental health SaaS provider, though its focus is on therapeutic content rather than assessment and triage.

Regional players

  • Cera Care: Large UK digital home healthcare provider using technology-enabled care services. Comparable as a UK digital health platform selling into NHS Trusts and integrated care systems with measurable efficiency outcomes.
  • Doctor Care Anywhere: UK-based digital health platform providing virtual consultations and mental health services. Comparable as a UK private/regulated digital health operator with NHS-facing relationships and enterprise distribution motion.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Psyomics social profiles

Digital presence

Psyomics compliance and trust

Trust signal

Compliance2 records

Psyomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Psyomics leadership team

Management profile

Number of profiles

Profiles4 records

Psyomics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Psyomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Psyomics

What does Psyomics do?

Psyomics sells AI-driven digital health assessment software (beseen and Censeo platforms) to healthcare providers for behavioral health and neurodiversity screening in adult, children and young people, and ADHD/autism pathways. The offering is delivered as a B2B SaaS subscription with EPR/EHR integration, implementation, and go-live support, and is augmented by an in-development dry blood spot Bipolar Biomarker test that combines metabolomic data with online questionnaires via machine learning.

Is Psyomics a public or private company?

Psyomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Psyomics founded?

Psyomics was founded in 2015. It employs 11 to 50 people.

Where is Psyomics based?

Psyomics is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Psyomics make money?

One revenue line is on record: saaS Platform Subscription.

Who are Psyomics's main competitors?

Direct peers on record are Limbic, Qbtech, Akili Interactive, Altoida, Cambridge Cognition, P1vital and Linus Health. SilverCloud Health (Amwell) is listed as a broad incumbent. Regional players are Cera Care and Doctor Care Anywhere.

Does Psyomics have an API?

No public API is recorded for Psyomics.

What industry is Psyomics in?

Psyomics's product category is Mental Health Assessment Software. Its primary akta.pro industry code is HLALAEAJ, Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching), with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 621511 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswirePsyomics appoints US digital health leader Raj Malik to Board to support next phase of growthPsyomics appointed Raj Malik to its Board to support growth in the UK and international expansion. Malik brings over 30 years of digital health experience, including scaling Rally Health to $2 billion in revenue. The company is expanding its digital mental health platform and preparing to launch biomarker technology.Med-Tech InsightsDerbyshire NHS Trust introduces digital platform for ADHD and autism assessmentsDerbyshire Healthcare NHS Foundation Trust is adopting beseen for Neurodiversity, a digital platform for ADHD and autism assessments, to address rising demand. The platform, developed with Psyomics, has been selected by 5 NHS Trusts since November 2025 and could cut assessment-related administration time by up to 30%.EIN PresswirePrecision Psychiatry Market Set to Reach More Than US$ 4.2 Billion by 2035 at 14.2% CAGR Driven by AI Integration| TMRThe global precision psychiatry market, valued at US$ 0.9 billion in 2024, is projected to exceed US$ 4.2 billion by 2035, growing at a compound annual growth rate of 14.2%, driven by AI integration, genomics adoption, and rising mental health disorder prevalence worldwide. The market shift from traditional symptom-based diagnosis to evidence-based, biologically informed strategies is accelerating adoption of genetic testing, biomarker analysis, neuroimaging, and AI-powered diagnostics across hospitals, clinical laboratories, and research institutions. Key recent developments include Polaris Genomics securing a second grant for PTSD genomic test validation, GeneDx publishing peer-reviewed study results supporting rapid genomic testing adoption, GrayMatters Health launching its Prism™ Suite depression protocol, and Psyomics Ltd partnering with the Priory Group to deploy its AI-driven Censeo platform at UK clinical locations.Healthcare TodayInnovation in healthcare roundup: CLEO Systems, Electiva, Psyomics, Corpora.aiThis roundup covers six healthcare innovation developments across the UK: CLEO Systems reported that pharmacists on NHS England's Pathfinder Independent Pharmacist Prescriber programme reported increased job satisfaction, with around 190 pharmacies now live using CLEO EPS for independent prescribing; Electiva Healthcare announced plans to open a flagship London hospital in summer 2025, projected to generate over £50 million in annual revenue and create 300 jobs; Psyomics launched a digital neurodiversity tool developed with Midlands Partnership University NHS Foundation Trust, claiming potential 30% reduction in clinical time; and MSTART and Corpora.ai partnered with the University of Warwick and Accelerated Clinical Trials to accelerate Acute Myeloid Leukaemia research using AI. Additionally, Calitii secured a managed services contract with biopharmaceutical company BridgeBio for ServiceNow platform support, while Worcestershire Acute Hospitals NHS Trust went live with Altera Digital Health's ePMA software across 56 inpatient wards.Health Tech WorldPsyomics launches beseen for neurodiversity in collaboration with Mids Partnership University NHSPsyomics has launched beseen for neurodiversity, a digital platform developed in collaboration with Midlands Partnership University NHS Foundation Trust to help NHS services manage rising neurodevelopmental referral backlogs. The platform covers ADHD, autism, and dual assessments for adults and young people, with early modelling suggesting a potential reduction of up to 30 per cent in clinical time by eliminating repetitive administrative tasks. The tool is designed to scale across NHS Trusts, Integrated Care Boards, and regional networks, integrating with existing NHS systems to streamline the referral process and improve patient care.EIN PresswirePsyomics Launches Healthtech Platform to Optimize Neurodiversity CarePsyomics, a UK-based digital health company, launched "beseen for neurodiversity," a digital assessment platform for ADHD and autism care, alongside a $5 million pre-Series A funding round. The platform, developed in collaboration with the UK's NHS and Cambridge University, has already reduced mental health waiting times by 31% (from 42 to 29 days) and cut clinical administrative time by 30%. The funding will support U.S. market expansion and FDA medical device accreditation.Med-Tech InsightsNorth London NHS Trust to 'revolutionise' mental health careNorth London NHS Foundation Trust has partnered with digital health company Psyomics to implement technology enabling easier access to mental health care across Barnet, Camden, Enfield, Haringey, and Islington, serving over 1.6 million residents. The Psyomics system captures patient-reported information including symptoms and social circumstances to help clinicians determine appropriate care pathways, with 25% of submissions occurring outside normal office hours to improve accessibility. The initiative is part of the Trust's wider transformation programme and is positioned as a potential national model for modernizing NHS mental health pathways.Business Wire BlogAI-informed mental health innovators Psyomics announce two big winsPsyomics announced a partnership with Priory to deploy its AI-informed platform Censeo as a digital triage tool for mental health care, following a successful pilot. Additionally, Psyomics won the 2024 Boston Consulting Group X Social Impact Accelerator Program to develop a version of the platform for children and young people. These developments aim to improve access to appropriate therapeutic care and optimize clinical pathways.LinkedIn#mentalhealth #mentalhealth #healthtech #psyomics #investment #healthcareinnovation #mentalhealthawarenessPsyomics has secured £4 million in fresh funding led by Parkwalk Advisors to advance its Censeo mental health platform. The investment will be used to expand the platform's capabilities to include specialist assessments for children and young people while reducing administrative burdens in mental health services. This move aims to address the growing demand for timely mental health support, particularly following the impact of the pandemic.